Mita, Tomoya
Katakami, Naoto
Shiraiwa, Toshihiko
Yoshii, Hidenori
Kuribayashi, Nobuichi
Osonoi, Takeshi
Kaneto, Hideaki
Kosugi, Keisuke
Umayahara, Yutaka
Gosho, Masahiko
Shimomura, Iichiro
Watada, Hirotaka
Article History
Received: 3 June 2016
Accepted: 29 November 2016
First Online: 9 January 2017
Competing interests
: TM received research funds from MSD and Takeda Pharma K.K. and has received lecture fees from AstraZeneca K.K., Boehringer Ingelheim, Eli Lilly, Kowa Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., MSD, Ono Pharmaceutical Co., and Takeda Pharmaceutical Co. NKa is a staff member of the endowed chair (Department of Metabolism and Atherosclerosis) established by funds from Kowa Pharmaceutical Co., has received research funds from MSD and lecture fees from Astellas Pharma Inc., AstraZeneca K.K., Boehringer Ingelheim, Daiichi Sankyo Inc., Dainippon Sumitomo Pharma Co., Eisai Co., Eli Lilly, Kowa Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Novartis Pharmaceuticals, Novo Nordisk Pharma, Ono Pharmaceutical Co., Otsuka Pharmaceutical, Shionogi & Co., Takeda Pharmaceutical Co., Sanofi-Aventis, and Shionogi & Co. TS has received lecture fees from Boehringer Ingelheim, Sanofi-Aventis, Novo Nordisk Pharma, Novartis Pharmaceuticals, Eli Lilly, Abbott Japan, Takeda Pharmaceutical Co., Sanwakagaku Kenkyusho, Mitsubishi Tanabe Pharma Co., Daiichi Sankyo Inc., Astellas Pharma Inc., Ono Pharmaceutical Co., MSD, Shionogi, Pharma, and Taisho Toyama Pharmaceutical Co. NKu has received lecture fees from Sanofi-Aventis and Novartis Pharmaceuticals. TOs has received lecture fees from Novo Nordisk, Inc., Astellas Pharma, Inc., Mitsubishi Tanabe Pharma, Sanwakagaku Kenkyusho, Takeda Pharmaceutical Co., Kowa Co. and research funds from Novo Nordisk, Inc., Astellas Pharma, Inc., Mitsubishi Tanabe Pharma, Sanwakagaku Kenkyusho, Kowa Co. Novo Nordisk Pharma, Dainippon Sumitomo Pharma., Eli Lilly Taisho Pharmaceutical Co., Ltd., GlaxoSmithKline, Sumitomo Dainippon Pharma Co., Ltd., Astellas Pharma US, Inc., Bayer HealthCare, and AbbVie GK. KK has received lecture fees from Boehringer Ingelheim, Sanofi-Aventis, Novo Nordisk Pharma, Novartis Pharmaceuticals, Eli Lilly, Takeda Pharmaceutical Co., MSD, Kowa Co., Mitsubishi Tanabe Pharma and research funds from Sysmex Co. HK has received lecture fees from Boehringer Ingelheim, Sanofi-Aventis, Ono Pharmaceutical Co., MSD, Novo Nordisk Pharma, Novartis Pharmaceuticals, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., Kissei Pharmaceutical Co., Dainippon Sumitomo Pharma Co., Mitsubishi Tanabe Pharma Co., Kyowa Kirin, Eli Lilly, Pfizer, Astrazeneca, Astellas Pharma Inc. and research funds from Takeda Pharmaceutical Co., MSD, Mochida Pharmaceutical Co. Sanofi-Aventis, Novartis Pharmaceuticals, Novo Nordisk Pharma, Eli Lilly, Daiichi Sankyo Inc., Shionogi Pharma, Teijin Pharma, Dainippon Sumitomo Pharma Co., Otsuka Pharmaceutical, Kissei Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Ono Pharmaceutical Co., Astrazeneca, Astellas Pharma Inc., and Kyowa Hakko Kirin Co. KK has received lecture fees from Boehringer Ingelheim, Sanofi-Aventis, Novo Nordisk Pharma, Novartis Pharmaceuticals, Eli Lilly, Takeda Pharmaceutical Co., MSD, Kowa Co., Mitsubishi Tanabe Pharma and research funds from Sysmex Co. MG received lecture fees from Novartis and Tiho Pharma K.K. and received travel fees from Takeda Pharmaceutical Co. and writing fee from Kowa Co., Ltd. IS has received lecture fees from Astellas Pharma Inc., AstraZeneca K.K., MSD K.K., Ono Pharmaceutical Co., Kyowa Hakko Kirin Co., Kowa Pharmaceutical Co., Sanofi K.K., Sanwa Kagaku Kenkyusho Co., Daiichi Sankyo Co., Takeda Pharma K.K., Mitsubishi Tanabe Pharma Co., Teijin Pharma, Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Novartis Pharma K.K., Novo Nordisk Pharma, Bayer Yakuhin, Pfizer Japan Inc., Bristol-Myers K.K., Mochida Pharmaceutical Co., Shionogi & Co., Taisho Toyama Pharmaceutical Co., Shionogi & Co., and research funds from Astellas Pharma Inc., AstraZeneca K.K., Eisai Co., MSD K.K, Otsuka Pharmaceutical Co., Ono Pharmaceutical Co., Kaken Pharmaceutical Co., Kissei Pharmaceutical Co., Kyowa Hakko Kirin Co., Sanofi K.K., Shionogi & Co., Daiichi Sankyo Co., Dainippon Sumitomo Pharma Co., Takeda Pharma K.K., Mitsubishi Tanabe Pharma Co., Teijin Pharma, Nippon Boehringer Ingelheim Co., Novartis Pharma K.K., Novo Nordisk Pharma, Pfizer Japan Inc., Bristol-Myers K.K., Mochida Pharmaceutical Co., Eli Lilly Japan K.K, Kowa Co., Ltd., Kowa Pharmaceutical Co., and Taisho Toyama Pharmaceutical Co. HW has received lecture fees from Novo Nordisk, Inc., Eli Lilly and Company, Sanofi, Dainippon Sumitomo Pharma Co., Fujifilm, Bayer Health Care, Kissei Pharmaceutical Company, Mochida Pharmaceutical Company, MSD, Takeda Pharmaceutical Company, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi-Sankyo, Ono Pharmaceutical Co., Ltd., Novartis Pharmaceuticals Corporation, Mitsubishi Tanabe Pharma Corporation, AstraZeneca LP, Kyowa Hakko Kirin Comapany, Ltd, Sanwa Kagaku Kenkyusyo Company, Ltd., Kowa Company Ltd, Astellas Pharma, Inc., advisory fees from Novo Nordisk, Inc., Mochida Pharma Company, AstraZeneca LP, Kowa Company, Astellas Pharma, Inc., Sanofi, Boehringer Ingelheim Pharmaceuticals, Inc., MSD, Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation, Dainippon Sumitomo Pharma Co, Takeda Pharmaceutical Company, Ono Pharmaceutical Co, Pfizer, Inc., Kowa Company and research funds from Boehringer Ingelheim, Pfizer, Mochida Pharmaceutical Co., Sanofi-Aventis, Novo Nordisk Pharma, Novartis Pharmaceuticals, Sanwakagaku Kenkyusho, Terumo Corp. Eli Lilly, Mitsubishi Tanabe Pharma, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., MSD, Shionogi, Pharma, Dainippon Sumitomo Pharma, Kissei Pharma, and Astrazeneca.